Atea Reports HCV Trial Positive and Receives $200M Non-Dilutive Funding
Atea announced positive HCV trial results and secured up to $200M in non-dilutive funding from Hercules Capital to advance clinical development.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed